XML 35 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 1,541.8 $ 1,331.2
Marketable securities 1,413.3 1,278.9
Accounts receivable, net 1,723.0 1,913.8
Due from anti-CD20 therapeutic programs 400.0 413.5
Inventory 1,347.9 1,068.6
Other current assets 736.3 881.1
Total current assets 7,162.3 6,887.1
Marketable securities 968.3 772.1
Property, plant and equipment, net 3,410.7 3,411.5
Operating lease assets 389.1 433.3
Intangible assets, net 2,286.8 3,084.3
Goodwill 5,760.5 5,762.1
Deferred tax asset 1,810.4 1,369.5
Investments and other assets 2,018.6 2,899.0
Total assets 23,806.7 24,618.9
Current liabilities:    
Current portion of notes payable 998.8 0.0
Taxes payable 234.2 142.0
Accounts payable 427.9 454.9
Accrued expense and other 2,550.7 3,145.3
Total current liabilities 4,211.6 3,742.2
Notes payable 6,272.3 7,426.2
Deferred tax liability 774.7 1,032.8
Long-term operating lease liabilities 348.2 402.0
Other long-term liabilities 1,318.2 1,329.6
Total liabilities 12,925.0 13,932.8
Commitments and contingencies
Biogen Idec Inc. shareholders' equity    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 0.0 0.0
Accumulated other comprehensive loss (136.6) (299.0)
Retained earnings 13,543.5 13,976.3
Treasury stock, at cost (2,977.1) (2,977.1)
Total Biogen Inc. shareholders’ equity 10,429.9 10,700.3
Noncontrolling interests 451.8 (14.2)
Total equity 10,881.7 10,686.1
Total liabilities and equity $ 23,806.7 $ 24,618.9